bluuebunny/crossref_metadata_2025_split huggingface dataset:
PB1992 HEMATOPOIETIC LIKE CELLS DERIVED FROM CANCER STEM CELLS GENERATED FROM MOUSE INDUCED PLURIPOTENT STEM CELLS: NOVEL CONCEPT FOR CANCER ASSOCIATED HEMATOPOIESIS
Authors: Hassan G. , Afify S.M. , Kumon K. , Zahra M. , Okada N. , Seno A. , Seno M. 
Published: June 2019

Background:Cancer stem cells (CSCs) represent the subpopulation of cancer cells with plasticity to differentiate into other cell phenotypes. Previously, we reported to generate cancer stem cells from mouse induced pluripotent stem cells with the potential to develop endothelial cells and cancer associated fibroblasts of angiogenesis. In the other hand, recent reports showed that erythrocytes could be derived from the tumor. However, the ability of CSCs to exhibit different hematopoietic cells is still unclear.Aims:To investigate the hematopoiesis phenomena from CSCs in vitro.Methods:Viability of non‐adherent cells (NACs) arising from cancer stem cells (expressing GFP under Nanog promoter) was analyzed by flow cytometry using Annexin V and PI. The morphology and expression of CD34 and LIN markers were also investigated using Giemsa staining, flow cytometry, and immunofluorescence staining, respectively. Molecular phenotype of NACs was examined by RT‐PCR. Clonogenic assay was conducted by culturing NACs on mouse embryonic fibroblast (MEF).Results:The round nucleated cells with heterogeneous diameter were observed on the surface of cancer stem cells adhered on the bottom of dish. Approximately 80% of NACs were found viable according to Annexin V and PI staining while 60% were positive for Lin markers and 0.35% were positive for CD34.NACs were found to express hematopoietic marker genes for CD34, CD38, CD10, c‐Kit and EPO‐R by RT‐PCR as well as to form colonies on MEF.Summary/Conclusion:CSCs were demonstrated to have potential to provide progenies with hematopoietic marker and morphology as cancer associated hematopoietic cells, which could give a new insight of tumor microenvironment according to the plasticity of cancer stem cells.
PB2003 ADDED RADIOTHERAPY IMPROVES PROGNOSIS IN HD PATIENTS TREATED WITH ABVD
Authors: Karanfilski O. , Amzai G. , Trpkovska Terzieva S. , Pavkovik M. , Sotirova T. , Genadieva Stavrik S. , Krstevska Balkanov S. , Cvetanoski M. , Ridova N. , Kocoski B. , Stojanovik A. 
Published: June 2019

Background:Results from many analyses and trials have shown that combined modality treatment contributes to better vital statistics for HD patients, compared to chemotherapy‐only treatment. In previous analyses, we have also argumented this point, validating it on our patient population. However, our previous analyses were performed mainly on HD patients initially treated with COPP‐like regimens.Aims:To analyze whether HD patients initially treated at our Clinic with the ABVD (and derived) regimen(s) still benefit from the addition of radiotherapy as a treatment component.Methods:Within the past two decades we used ABVD as initial treatment in a total of 272 HD patients. In more than 70% of these, chemotherapy only was the treatment mode administered. Almost 30% of these patients required addition of radiotherapy, as part of a recommended combined modality treatment option, or, in a minority of cases, as adjuvant treatment to sites of residual or bulky tumor mass.Results:ABVD as induction treatment achieves 5yOS in 91% of patients, and 10yOS for 85% of the patients. The survival curve maintains a plateau at 82.5% after the 150‐month mark. The 77 patients treated with the combined modality treatment/adjuvant chemotherapy maintain a 4% margin of superiority in the OS, across the first 10 years of follow‐up. Nevertheless, both survival curves almost merge after the 15th year, and maintain a continuous plateau thereafter. The benefit is more evident when PFS is analyzed. All clinical stages maintain a continuous difference between the plateaus of the curves, starting from the third year of follow‐up, varying from 2‐6% among different CS categories. Although a small category (8 patients), even the advanced stage patients treated with adjuvant radiotherapy benefit from this option, maintaining a 100% OS and PFS line. It should be clearly stated that in our analysis the differences do not reach a statistically significant level in terms of p‐values, probably due to the relatively small number of patients analyzed, the notable disproportion among the patients with completed vs. censored observations, as well as because of the numeric misbalance among the groups treated with the two treatment options.Summary/Conclusion:Having balanced all observations, we still recommend that radiotherapy is not omitted as a very beneficial mode of treatment across all stages of the disease (abiding firmly by the indications for evidence‐based utilization of this option), contributing to a (maybe) marginal, but still a continuous advantage in the vital statistics of HD patients. Not neglecting the everlasting concerns of the community with regard to the adverse late effects of radiotherapy, hopes should turn towards dose modifications and field adjustments, as well as technological improvements of radiotherapy, rather than abandoning this treatment modality.
PB2004 A 15 YEAR RETROSPECTIVE STUDY OF HODGKIN LYMPHOMA PATIENTS IN ALBANIA
Authors: Cili A. , Leart B. , Petrela E. , Perolla A. , Tozharaku R. , Polikron P. , Calliku E. , Caja T. , Ivanaj A. 
Published: June 2019

Background:Hodgkin lymphoma (HL) is a lymphoid malignancy of B‐cell origin. HL is a rare neoplasm with an incidence that varies significantly by age, sex, ethnicity, geographic location and socioeconomic status.Aims:We have made a 15 year retrospective study in Albania where we studied the incidence, treatment, treatment response and OS (overall survival) of Hodgkin LymphomaMethods:We have analysed the adult patients with Hodgkin Lymphoma from 2003 till 2018 registered in the statistic center in the University Hospital Center “Mother Teresa” and in the “Cancer registry” at ISHP (Public Health Institute) at the moment of diagnosis, the protocol treatment used, the patients response and the overall survival. Overall survival was calculated with Kaplan‐Meier method.Results:From the 2003‐2018 in Albania are diagnosed and treated for the first time 331 patients with Hodgkin Lymphoma and 169 of them were male patients (51%) and 162 were female patients (49%) with M/F ratio of 1.04. The median age was 37 years old (Range 14‐65 years old).The highest incidence was in 2012 with 0.82 per 100000 adult residents. According to Ann Arbour classification 17 patients (5.1%) were classified stage IA, 4 patients (1.2%) were classified stage IB, 113 patients (34.1%) were classified stage IIA, 72 patients (21.7%) were classified stage IIB, 20 patients (6.0 %) were classified stage IIIA, 61 patients (18.4%) were classified stage IIIB,6 patients (1.81 %) were classified stage IVA, and 38 patients (11.4%) were classified stage IVB.Histology classification: 63% of patients were classified as nodular sclerosis (NS), 12% were classified as nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), 22 % were classified as mixed cellularity (MC),and 3 % were classified as lymphocyte‐depleted (LD).Treatment protocols. As first line treatment protocol in Albania we use ABVD protocol (adriamycin, bleomycin, vinblastine, dacarbazine) and ABVD plus RT (radiotherapy). From all the patients 160 (48.3%) were treated with ABVD and 165 (49.7%) were treated with ABVD plud RT. Response data was available for all patients; complete response in 84% of patients; partial response in 10 % of our patients and progressive disease in 6% of our patients.Summary/Conclusion:Conclusion: Lymphoma incidence in Albania is 0.8 per 100 000 adult residents. ABVD is widely accepted as a standard treatment option for Hodgkin's lymphoma, and this study shows that comparable results can be reproduced in our patients with acceptable tolerance. There is no difference in OS (overall survival) between patients treated with ABVD and patients treated with ABVD + RT. OS (Overall survival) is 59% at 14.1 years of follow up realizing that ABVD is a good regimen. The most important information of this study lies in the fact that this is the largest data from Albania on patients diagnosed with Hodgkin Lymphoma on ABVD protocol treatment.imageOS (Overall survival) is 59% at 14.1 years
PB2029 HEPATITIS B REACTIVATION DURING TREATMENT OF TYROSINE KINASE INHIBITORS—EXPERIENCE IN 175 ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA
Authors: Wang Y.‐H. , Liang J.‐D. , Sheng W.‐H. , Tien F.‐M. , Chen C.‐Y. , Tang J.‐L. , Tien H.‐F. 
Published: June 2019

Background:The cause of hepatitis B virus (HBV) reactivation in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) is unclear.Aims:Taiwan has a high prevalence of HBV infection, and this study aimed to investigate the epidemiology of HBV reactivation in patients with CML treated with TKIs.Methods:We retrospectively reviewed 175 adult patients with CML who were treated using TKIs at National Taiwan University Hospital between January 2008 and July 2018. HBV infection status and reactivation were reviewed during follow‐up.Results:A total of 99 men and 76 women with a median age of 46 years (range: 18–97) were enrolled in this study. Twenty‐one (12%) of 175 patients were carrying HBV when they were diagnosed with CML. Eight HBV carriers were prophylactically treated using an antiviral agent, and the others were closely followed‐up. At a median follow‐up period of 41 months (range 1–129 months), 6 (28.6%) of the 21 HBV carriers had 7 episodes of HBV reactivation. Two (1.3%) of the 154 negative hepatitis B surface antigen (HBsAg) patients had reverse seroconversion and became positive HBsAg, and both patients had acute blastic transformation and allogeneic transplantation. A univariate analysis revealed positive HBsAg and negative anti‐Hepatitis B surface antibodies (anti‐HBs Ab) significantly correlated with HBV reactivation. In this retrospective cohort study, the incidence of HBV reactivation was 0.5 per 100 person‐years in patients with CML carrying HBV who had been treated with TKIs and 0.076 per 100 person‐years in all patients with CML treated with TKIs.Summary/Conclusion:HBV reactivation could develop in patients with CML treated with TKI, especially in those who are HBV carriers. The incidence is lower than it is in hematological patients with HBV carrier status who have been treated with chemotherapy, immunotherapy and stem cell transplantation. We suggest that all patients with CML with positive HBsAg undergo prophylaxis with an antiviral agent. The cause of HBV reactivation in patients with resolved HBV infection and no allogeneic transplantation is unclear, and although the risk is low, further investigation is required.image
PB2035 ISAVUCONAZOLE AS PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS IN STEM CELL TRANSPLANT PATIENTS: A DESCRIPTIVE SINGLE CENTER EXPERIENCE.
Authors: Pinzon S.F. , Marta V.M. , Izquierdo I. , Aules A. , Salvador E. , Garcia Ortego A. , Diez R. , Delgado P. 
Published: June 2019

Background:Isavuconazole is a novel triazole antifungal approved for treating invasive aspergillosis and mucormycosis with predictable pharmacokinetics compared to its counterparts; the handling of interactions with other medications is easier, which is the most important advantage of this antifungal. The aim of our study is to describe the experience with this Triazole in prophylaxis in our hospital.Aims:The aim of this study its to describe our experiencie with Isovuconazole.Methods:A retrospective review from the patients undergoing allogenic stem cell transplantation who received Isavuconazole in prophylaxis was performed. We analyze the demographic data and the risk factors related to the host, disease, treatment and the transplant.Results:From a sample of 6 patients with a main age of 52 age years, equal sex ratio, five patients have an acute myeloid leukemia (ALM) and one patient a myelodysplastic syndrome (MDS), all the patients has at least one high risk factor for the development of invasive fungal infections (IFI), described in the table 1. All of them was taking corticosteroids due to chronic/acute GVHD and one patient because of an autoimmune disease.All patients were treated with oral Isavuconazole at 200 mg per day at least 14 days for prophylaxis; the reasons to choose Isavuconazole were elevated liver transaminases in four cases and Posaconazole intolerance in two patients.Serum detection of galactomannan was performed for all patients every week during antifungal therapy and all the results were negative.Summary/Conclusion:Although the efficacy and safety of Isavuconazole, there is no indication in the technical sheet for prophylaxis with this triazole. At this time, none of our patients developed an IFI or intolerance to treatment. There are few studies that evaluate prophylaxis, most related to the experience in solid organ transplantation, but it is not known what is happening in the real world of hematological diseases. In our experience seems to be a useful and safe drug, however, more studies are needed to verify this hypothesis.image
PB2036 EFFECTS OF DIFFERENT IRON FORMULATION SUPPORT ON SELECTION OF SOME PATHOGENS IN HUMAN GUT FLORA: MONOCENTRIC STUDY
Authors: Giordano G. , Lucchesi A. , magri M. , niro G. , gasperi M. 
Published: June 2019

Background:Food and micronutrients support modify the composition of our intestinal flora.Aims:Aim of this study is to see how different iron formulations used in human iron support are able to expand gut pathogen flora.Methods:36 female patients (6 per group) with sideropenic anemia due to hypermenorrhea received 60 mg/day of different iron formulations: sulphate, Sucrosomial®, heminic bisglycinated, bisglycinated chelated, micronized encapsulated.Median age of patients was 30y (R20‐38). A stool culture test was performed in each patient at start of treatment and one month after. If at time 0 a culture was positive for a pathogen, patient was excluded from the study.Cultural stool test were performed for E. coli enteropathogen, enterohemorragic, salmonella, shigella, clostridium, yersinia entherocolica.Results:Before treatment: 1 patient receiving iron sulphate had a yersinia positivity and 1 receiving heminic bisglycinated iron showed an E. coli.After treatment: 2 patients receiving heminic bisglycynated iron showed positivity for E. coli enteropathogenic, 1 for shigella; 4 patients receiving iron sulphate showed positivity for E. coli enteropathogenic; 2 patients receiving micronized encapsulated iron and 2 with bisglycinated chelated iron showed positivity for E. coli enteropathogenic, 1 with Sucrosomial® iron showed positivity for yersinia enterocolica.Summary/Conclusion:Different type of iron supplements differently affect pathogen gut flora selection. Molecular complexes iron carriers probably influence differently pathogen selection. The most represented selected pathogen flora is E. coli entheropathogenic.
PB2040 EMERGENT INFECTIONS ASSOCIATED TO THE TREATMENT WITH NEW MOLECULES IN CHRONIC LYMPHOCYTIC LEUKEMIA ‐ SINGLE CENTER EXPERIENCE
Authors: Tomescu A.A. , Enache A. , Dragan R. , Vasilica M. , Coriu D. , Ursuleac I. 
Published: June 2019

Background:During the last years, the overall response to the treatment of patients with chronic lymphocytic leukemia (CLL) has improved due to the introduction in the therapeutical armentarium of the new molecules ‐ Bruton kinase (BTK) inhibitors (Ibrutinib) and Phosphoinositide 3‐kinases (PI3Ks) inhibitors ‐ Idelalisib. The main late adverse reaction of the treatment with these 2 products is immunosupression with high infectious risk, including viral reactivations and opportunistic de novo infections (bacterial, mycotic or viral).Aims:To find the risk factors associated to the risk of infections in CLL patients treated with new moleculesMethods:A retrospective, clinico‐epidemiological study including 12 CLL patients diagnosed in our centre with various infections during therapy with Idelalisib or Ibrutinib.Results:12 CLL patients (6 men, 6 women) have been observed: 2 treated with Idelalisib 150 mg BID and 10 treated with Ibrutinib 420 mg QD; median age ‐ 56 years (35 – 75). There have been studied: the number of anterior therapeutic lines (2 – 5 patients, 3 – 5 patients, 4 – 2 patients), treatment‐free period before new molecules have been introduced (medium 15 months), therapy duration before the onset of the infection (19 months medium); additional risk factors ‐ previous hypogammaglobulinemia (observed in all the studied patients). We have identified viral reactivations (CMV, VZV, HSV), fungal (Aspergillus sp.) and bacterial (Klebsiella sp., E. coli, Corynebacterium bovis, MRSA) infections. The localizations were: cerebral (2 cases of aspergillosis and CMV), pulmonary (3 cases of aspergillosis), genito‐urinary (3 cases of multiresistent E. coli and HSV) and cutaneous (2 cases of HSV and MRSA). 5 deaths occurred due to uncontrolled disease and infection.Summary/Conclusion:Treatment with new molecules is associated with high infectious risk. We have identified multiple causes: advanced stage of disease, heavily treated patiens, hypogammaglobulinemia and comorbidities (diabetes). These patients should be closely monitored for infectious risk during treatment with new molecules.
PB2045 EFFICACY & SAFETY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN IRON DEFICIENCY ANEMIA: A PROSPECTIVE STUDY
Authors: Nath U.K. , Chetia R. 
Published: June 2019

Background:Iron deficiency anemia (IDA) is the most common nutritional anemia globally. Goal of iron replacement therapy are correction of anemia and repletion of body iron stores. Oral iron replacement is the preferred route in general. However, response to oral iron replacement therapy is often suboptimal due to poor compliance to treatment resulting from gastrointestinal intolerance and prolonged duration of oral iron therapy. Ferric carboxymaltose is a relatively recently approved parenteral iron formulation which can be administered in large doses of upto 1000 mg in a single infusion.Aims:The present study describes the efficacy & safety of intravenous ferric carboxymaltose for treatment of iron deficiency anemia in a tertiary institution in India.Methods:This non‐randomised prospective study included 77 patients of age ≥ 12 years with confirmed diagnosis of iron deficiency anemia between January 2018 & January 2019. Detailed history was taken & examination performed for signs & etiology of IDA. The cut‐off serum ferritin level for IDA diagnosis was < 15 ng/ml. Pregnant females and patients with concurrent vitamin B12 deficiency were excluded. All patients were treated with Injection Ferric Carboxymaltose (FCM) by I.V. infusion over 30 minutes in day care. Total dose of parenteral iron was calculated according to Ganzoni Formula: Total iron deficit (mg) = 2.4 x body weight (kg) x [target haemoglobin – actual haemoglobin (g/dl)] + 500 mg (depot iron). The maximum dose of FCM administered in a single infusion was 1000 mg. Patients with total iron dose > 1000 mg received two divided doses one week apart. Patients also received oral folic acid at 5 mg/day dose for at least 3 weeks. Appropriate workup for etiology of IDA was performed in all patients. Therapeutic response was assessed after 3 weeks of first FCM dose & was defined as hemoglobin increase of ≥ 2 g/dl from baseline.Results:The median age of patients was 33 years (range 16 ‐ 75 years) and majority (78%) were females. The median baseline hemoglobin was 5 g/dl (range 2.0 ‐ 8.6 g/dl). Therapeutic response was achieved in 100% patients. Mean increase in haemoglobin at 3 weeks was 4.2 g/dl (range 2.8 ‐ 5.5 g/dl). One patient had mild headache during FCM infusion. There was no infusion‐related toxicity or any other adverse event.Summary/Conclusion:In our study, intravenous ferric carboxymaltose was found to be highly effective & safe alternative to oral iron for treatment of iron deficiency anemia, with excellent patient compliance. It is ideally suited for patients who require rapid replenishment of iron stores.
PB2071 GENETIC VARIATIONS IN TUMOR NECROSIS FACTOR‐RELATED APOPTOSIS‐INDUCING LIGAND RECEPTOR‐1 (TRAIL‐R1) GENE AND THE SUSCEPTIBILITY TO B CELL NON‐HODGKIN LYMPHOMA IN EGYPT
Authors: Khorshied M. , Soliman N. , Bakr S. , Khorshid O. 
Published: June 2019

Background:Apoptosis is essential for normal tissue homeostasis, cellular differentiation and development. Inhibition or blockade of Tumor Necrosis Factor‐Related Apoptosis‐Inducing Ligand‐Receptor 1 (TRAIL‐R1) may alter its apoptotic function, and subsequently provide growth advantage to neoplastic cells. Genetic polymorphisms in TRAIL‐R1 gene were involved with susceptibility to many cancers, however dearth of reports about B‐non‐Hodgkin lymphomas (B‐NHLs) particularly from Arab African nations.Aims:To assess the possible association between TRAIL‐R1 ‐A1322G, ‐C626G and ‐A683 C and polymorphisms and B‐NHL risk among Egyptians.MethodsGenotyping of TRAIL‐R1 ‐C626G, ‐A683 C and ‐A683 C was performed to 100 B‐NHL patients and 150 controls.Results:The frequency of polymorphic alleles of ‐A1322G and ‐C626G was higher in B‐NHL compared to controls with almost twofold increased risk of B‐NHL (OR = 2.04; 95%CI = 1.02‐4.07 and OR = 1.76; 95%CI = 1.01‐3.07 respectively), while there was no statistical difference in the distribution of ‐A683 C polymorphic allele (OR = 1; 95%CI = 0.5‐2). Combined genotypes analysis revealed that co‐existence of the three variants conferred fourfold increased risk (OR = 4.1; 95% CI = 1.01‐17.63), while co‐inheritance of ‐C626G and ‐A1322G, and co‐inheritance of ‐A683 C and ‐A1322G conferred fivefold and threefold increased the risk respectively.Summary/Conclusion:TRAIL‐R1–C626G and ‐A1322G polymorphisms could be considered as molecular risk factors for B‐NHL in Egyptian population. Furthermore, the growing interest in TRAIL‐based interventions has led to the development of recombinant human TRAIL (rhTRAIL) as a promising target therapy. Accordingly, screening for TRAIL‐R1 gene polymorphisms is mandatory for selecting patients who will gain benefit from this novel therapeutic modality